AnaptysBio Statistics
Total Valuation
AnaptysBio has a market cap or net worth of $581.14 million. The enterprise value is $565.23 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AnaptysBio has 30.67 million shares outstanding. The number of shares has increased by 5.42% in one year.
| Current Share Class | 30.67M |
| Shares Outstanding | 30.67M |
| Shares Change (YoY) | +5.42% |
| Shares Change (QoQ) | +5.38% |
| Owned by Insiders (%) | 2.15% |
| Owned by Institutions (%) | 88.68% |
| Float | 18.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.89 |
| Forward PS | 15.14 |
| PB Ratio | 8.15 |
| P/TBV Ratio | 8.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.51, with a Debt / Equity ratio of 5.21.
| Current Ratio | 9.51 |
| Quick Ratio | 9.38 |
| Debt / Equity | 5.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.29 |
Financial Efficiency
Return on equity (ROE) is -182.71% and return on invested capital (ROIC) is -16.77%.
| Return on Equity (ROE) | -182.71% |
| Return on Assets (ROA) | -15.35% |
| Return on Invested Capital (ROIC) | -16.77% |
| Return on Capital Employed (ROCE) | -26.22% |
| Revenue Per Employee | $671,176 |
| Profits Per Employee | -$1.07M |
| Employee Count | 136 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AnaptysBio has paid $3,000 in taxes.
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.37% in the last 52 weeks. The beta is 0.02, so AnaptysBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.02 |
| 52-Week Price Change | -11.37% |
| 50-Day Moving Average | 17.01 |
| 200-Day Moving Average | 25.15 |
| Relative Strength Index (RSI) | 59.57 |
| Average Volume (20 Days) | 928,325 |
Short Selling Information
The latest short interest is 9.31 million, so 30.35% of the outstanding shares have been sold short.
| Short Interest | 9.31M |
| Short Previous Month | 6.03M |
| Short % of Shares Out | 30.35% |
| Short % of Float | 51.62% |
| Short Ratio (days to cover) | 12.83 |
Income Statement
In the last 12 months, AnaptysBio had revenue of $91.28 million and -$145.23 million in losses. Loss per share was -$5.12.
| Revenue | 91.28M |
| Gross Profit | -72.56M |
| Operating Income | -114.95M |
| Pretax Income | -170.11M |
| Net Income | -145.23M |
| EBITDA | -114.34M |
| EBIT | -114.95M |
| Loss Per Share | -$5.12 |
Full Income StatementBalance Sheet
The company has $385.37 million in cash and $369.46 million in debt, giving a net cash position of $15.91 million or $0.52 per share.
| Cash & Cash Equivalents | 385.37M |
| Total Debt | 369.46M |
| Net Cash | 15.91M |
| Net Cash Per Share | $0.52 |
| Equity (Book Value) | 70.87M |
| Book Value Per Share | 2.33 |
| Working Capital | 386.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$135.34 million and capital expenditures -$358,000, giving a free cash flow of -$135.70 million.
| Operating Cash Flow | -135.34M |
| Capital Expenditures | -358,000 |
| Free Cash Flow | -135.70M |
| FCF Per Share | -$4.42 |
Full Cash Flow StatementMargins
Gross margin is -79.49%, with operating and profit margins of -125.93% and -159.10%.
| Gross Margin | -79.49% |
| Operating Margin | -125.93% |
| Pretax Margin | -159.10% |
| Profit Margin | -159.10% |
| EBITDA Margin | -125.27% |
| EBIT Margin | -125.93% |
| FCF Margin | n/a |
Dividends & Yields
AnaptysBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.42% |
| Shareholder Yield | n/a |
| Earnings Yield | -24.99% |
| FCF Yield | -23.35% |
Analyst Forecast
The average price target for AnaptysBio is $36.38, which is 91.98% higher than the current price. The consensus rating is "Buy".
| Price Target | $36.38 |
| Price Target Difference | 91.98% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 11.02% |
| EPS Growth Forecast (5Y) | 0.79% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AnaptysBio has an Altman Z-Score of -0.75 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.75 |
| Piotroski F-Score | 3 |